Product image of Olmita (Olmesartan Medoxomil, Amlodipine) supplied by GNH India

Olmita

Active Ingredient:
Olmesartan Medoxomil, Amlodipine
Origin:
EU

Olmita (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil and amlodipine, the active ingredient in Olmita, is a Angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) combination presented as a fixed-dose oral tablet for oral use. It is indicated for the treatment of hypertension in adult patients. GNH India supplies Olmita as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Krka-Farma D.O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olmita, a combination antihypertensive, is indicated for conditions involving elevated blood pressure.

  • Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension.
  • High‑risk hypertension: improves blood pressure control in patients with cardiovascular risk factors.
  • Adjunctive therapy for resistant hypertension: can be added when monotherapy does not achieve target pressure.

How It Works

  • Olmesartan medoxomil selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Amlodipine inhibits L‑type calcium channels in vascular smooth muscle, leading to arterial dilation. The combined effect reduces peripheral resistance and lowers blood pressure more effectively than either component alone.

Side Effects

Common side effects are generally mild and related to vasodilation or fluid balance.

Common Side Effects

  • Dizziness: sensation of light‑headedness, especially after standing.
  • Headache: mild to moderate intensity.
  • Peripheral edema: swelling of ankles or lower legs.
  • Flushing: transient warmth and redness of the skin.
  • Fatigue: feeling unusually tired.
  • Palpitations: awareness of heartbeat.

Serious or Rare Side Effects

  • Angioedema: rapid swelling of face, lips, tongue, or throat.
  • Severe hypotension: marked drop in blood pressure causing faintness.
  • Hepatic dysfunction: abnormal liver enzymes or jaundice.
  • Acute kidney injury: sudden reduction in renal function.
  • Myocardial infarction: chest pain indicative of heart attack.

Precautions & Warnings

Before initiating Olmita, clinicians should assess individual risk factors and monitor patients regularly.

  • Blood pressure monitoring: check BP after dose adjustments.
  • Renal function: evaluate serum creatinine and eGFR periodically.
  • Electrolytes: monitor potassium levels, especially if combined with potassium‑sparing agents.
  • Hepatic impairment: use caution in patients with moderate to severe liver disease.
  • Pregnancy: avoid use unless clearly needed; safety not established.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Avoid Interactions

Olmita may interact with several medicines that affect blood pressure, renal function, or drug metabolism.

Major Interactions (Avoid)

  • ACE inhibitors or other ARBs: increased risk of hyperkalemia and renal impairment.
  • NSAIDs: may blunt antihypertensive effect and worsen renal function.
  • Potassium‑sparing diuretics: heightened risk of hyperkalemia.
  • Cyclosporine or tacrolimus: can raise olmesartan plasma concentrations.
  • High‑dose simvastatin: amlodipine can increase statin levels, raising myopathy risk.

Moderate Interactions (Monitor Closely)

  • Thiazide or loop diuretics: additive blood‑pressure lowering effect.
  • Beta‑blockers: may enhance overall antihypertensive response.
  • Rifampin: may reduce olmesartan exposure.
  • Digoxin: amlodipine can increase digoxin levels.
  • Alcohol: may potentiate dizziness and hypotension.

Frequently Asked Questions

Olmita is a prescription medication that combines olmesartan medoxomil and amlodipine to treat hypertension. The two agents work together to lower high blood pressure, helping to reduce the risk of cardiovascular events such as stroke or heart attack in adult patients.

Olmesartan medoxomil blocks the angiotensin II type 1 (AT1) receptors on blood vessels, preventing angiotensin II from causing vasoconstriction and aldosterone release. This leads to relaxation of the vessels and a decrease in blood pressure.

The dose of Olmita is individualized by the prescribing clinician based on the patient’s blood‑pressure goals, prior therapy, and tolerability. The prescriber determines the appropriate strength and dosing schedule for each patient.

Safety of Olmita in pregnancy has not been established, and it is generally avoided unless the potential benefit justifies the risk. Limited data are available for breastfeeding; the decision to use it should be made by a healthcare professional after weighing risks and benefits.

To order Olmita, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Olmita combines an ARB (olmesartan) with a calcium‑channel blocker (amlodipine), offering a dual mechanism that can provide more consistent blood‑pressure control than single‑agent therapy. Compared with monotherapy, the fixed‑dose combo may improve adherence and achieve target pressures with fewer tablets.

Olmita tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Keep the container tightly closed and protect the tablets from moisture and direct sunlight to maintain potency.

Olmita is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing instructions provided by their healthcare professional.

Serious risks include angioedema (rapid swelling of the face, lips, tongue, or throat), severe hypotension, hepatic dysfunction, and acute kidney injury. Patients should seek immediate medical attention if they experience symptoms such as swelling, difficulty breathing, sudden dizziness, or marked loss of urine output.

Olmita should be avoided in patients with known hypersensitivity to olmesartan, amlodipine, or any component of the formulation. It is also contraindicated in individuals with severe hepatic impairment, and it should be used with caution in patients with renal insufficiency or a history of angioedema.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Amlodipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT